How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

746 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Obesity in Adolescents

agents in the management of obesity in adolescents. Medical therapies are most often employed for adolescents who have not responded to lifestyle changes or for those with medical comorbidities. Only tetrahydrolipstatin is approved by the U.S. Food and Drug Administration for use in adolescents and it is considered the first-line adjunct to behavioral interventions ( ). Sibutramine was voluntarily withdrawn from the market in 2010 because of cardiovascular concerns (82). Tetrahydrolipstatin

2017 American College of Obstetricians and Gynecologists

62. Is there any evidence to support the use of sibutramine as an antidepressant?

Is there any evidence to support the use of sibutramine as an antidepressant? Is there any evidence to support the use of sibutramine as an antidepressant? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing (...) including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence to support the use of sibutramine as an antidepressant? In 2001 NHS Tayside published a prescribing review of sibutramine [1], reporting: “Sibutramine is a new anti-obesity agent, which at first glance seems

2008 TRIP Answers

63. Can sibutramine and orlistat be combined in severe cases of obesity?

Can sibutramine and orlistat be combined in severe cases of obesity? Can sibutramine and orlistat be combined in severe cases of obesity? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Can sibutramine and orlistat be combined in severe cases of obesity? The CKS guideline on obesity considers the combination of sibutramine and orlistat and states: " There is evidence from one study to suggest that the addition of orlistat to sibutramine does

2008 TRIP Answers

66. Drugs That May Cause or Exacerbate Heart Failure

suppressants x Major A Valvular damage Intermediate Fenfluramine, dexfenfluramine, and sibutramine have been removed from the US market Bipolar medications Lithium x Major C Direct myofibrillar degeneration, adrenergic stimulation, calcium ion influx interference Intermediate to delayed Reversible on discontinuation Ophthalmological medications Topical β-blockers x Major C Negative inotrope Immediate to intermediate Consider lowering the dose or discontinuing; reversible on discontinuation Topical

Full Text available with Trip Pro

2016 American Heart Association

67. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association

committee cautions against the use of ephedra, sibutramine, and other weight-loss prepara- tions because they may contribute to the development of HF and should be avoided. 8 Currently, given the above concerns and the lack of evidence on intentional weight loss in HF, the 2009 AHA scientific statement on promoting self-care in individu- als with HF suggests weight loss only if the BMI is >40 kg/m 2 . 249 If the BMI is 35 kg/m 2 , gastrointestinal surgery may be an option. Additionally, in patients (...) or physical activity for the pur- poses of improving health-related QOL or managing comorbidities such as diabetes mellitus, hypertension, or sleep apnea may be reasonable in obese patients with HF (Class IIb; Level of Evidence C). 2. Sibutramine or ephedra weight loss prepara- tions are contraindicated in HF . Use of ephedra weight-loss preparations may contribute to the development of HF and should be avoided (Class III: Harm; Level of Evidence C). No Data Weight reduction, including with bariatric

Full Text available with Trip Pro

2016 American Heart Association

68. Drugs for Type 2 Diabetes – Project Protocol

of interest outlined in Table 3. Interventions of interest, including fixed-dose combinations and mixed insulin products are further detailed in Tables 1 and 2. Detailed eligibility criteria for studies are provided in Table 4. Studies will not be excluded based on outcomes reported. Weight-loss drugs (e.g., orlistat, sibutramine) included in previous CADTH reviews will not be included in this update. The primary role of such drugs is to lower body weight rather than to treat hyperglycemia. Table 3

2016 CADTH - Therapeutic Review

70. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

; RR = rel- ative risk; RYGB = Roux-en-Y gastric bypass; SAD = sagittal abdominal diameter; SBP = systolic blood pres- sure; SCOUT = Sibutramine Cardiovascular Outcome Trial; SG = sleeve gastrectomy; SHBG = sex hormone- binding globulin; SIEDY = Structured Interview on Erectile Dysfunction; SNRI = serotonin-norepinephrine reuptake inhibitors; SOS = Swedish Obese Subjects; SS = surveillance study; SSRI = selective serotonin reuptake inhibitors; STORM = Sibutramine Trial on Obesity Reduction

2016 American Association of Clinical Endocrinologists

72. Naltrexone + bupropion (Mysimba°): too risky for only modest weight loss

. Sibutramine: cardiovascular events Prescrire Int 2010; 19 (107): 125. Obesity: weight loss without drugs Prescrire Int 2007; 16 (90): 162-167. | | | Prescrire Your change of address has been received and will be processed promptly but will not appear instantaneously Prescrire Your message has been sent

2015 Prescrire

73. Obesity: European patients protected against lorcaserin, a psychotropic drug sold as an appetite suppressant

) Benfluorex: the appetite- suppressant amphetamine is finally suspended from sale in France (November 2009) Sibutramine: withdrawn from the European market at last! (July 2010) Obesity: diet, physical exercise and support are the priorities (April 2009) Rimonabant: marketing authorisation suspended... at last! Prescrire Int 2009; 18 (100) : 61. | | | Prescrire Your change of address has been received and will be processed promptly but will not appear instantaneously Prescrire Your message has been sent

2014 Prescrire

74. BMI Reduction and Chronic Disease Management

from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012 Jun;14(6):523-30. PubMed: PM22192338 20. Shea MK, Nicklas BJ, Houston DK, Miller ME, Davis CC, Kitzman DW, et al. The effect of intentional weight loss on all-cause mortality in older adults: results of a randomized BMI Reduction for Chronic Disease Management 4 controlled weight-loss trial. Am J Clin Nutr [Internet]. 2011 Sep [cited 2014 Apr 16];94(3):839-46. Available from: http://www.ncbi.nlm.nih.gov/pmc

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

75. Centrally-acting drugs for obesity cause more harm than good

products (16 trials with 24,555 participants) – three (lorcaserin, naltrexone-bupropion and phentermine-topiramate ) of which are currently available and two (rimonabant and sibutramine) withdrawn from the market because of serious adverse reactions. Centrally acting medicines increased the chance of losing at least 5% of body weight, but their use was associated with increased risk of harms and discontinuation because of these harms. In particular, the risk of nervous and psychiatric adverse events

2018 Evidence-Based Medicine blog

76. "Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"

"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention" "Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention" - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. "Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention" (AOS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01023139

2009 Clinical Trials

77. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. (PubMed)

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. The objective of this article was to estimate the risk of discontinuation due to adverse events in trials of orlistat, sibutramine and rimonabant. Medline, EMBASE, the Cochrane controlled trials register and reference lists of identified articles were searched from 1990 to May 2008. All randomized placebo-controlled trials of 12-24 months of duration on adults using licensed (...) sibutramine and 5 rimonabant). The risk ratios for discontinuation due to adverse events were significantly elevated for rimonabant (2.00; 1.66-2.41) and orlistat (1.59; 1.21-2.08), but not sibutramine (0.98, 0.68-1.41). Compared with placebo, the risk difference was the largest for rimonabant (7%, 5-9%; NNH 14, 11-19), followed by orlistat (3%, 1-4%; NNH 39, 25-83), while no significant difference was seen for sibutramine (0.2%, -3 to 4%; NNH 500). The most common adverse events leading to withdrawal

2009 Obesity reviews : an official journal of the International Association for the Study of Obesity

78. 5-HT(1A) Activation Counteracts Cardiovascular But Not Hypophagic Effects of Sibutramine in Rats. (PubMed)

5-HT(1A) Activation Counteracts Cardiovascular But Not Hypophagic Effects of Sibutramine in Rats. The noradrenaline (NA) and serotonin reuptake inhibitor, sibutramine, gives effective weight loss, but full efficacy cannot be attained at approved doses due to cardiovascular side effects. We assessed in rats the contributions of NA and serotonin transporters to sibutramine's hypophagic and cardiovascular effects, and whether selective 5-hydroxytryptamine (5-HT(1A)) receptor activation could (...) counteract the latter without affecting the former. Food intake was assessed in freely feeding rats and cardiovascular parameters in conscious telemetered rats. Ex vivo radioligand binding was used to estimate brain monoamine transporter occupancy. Sibutramine (1-10 mg/kg p.o.) dose-dependently reduced food intake; however, 10 mg/kg p.o. markedly elevated blood pressure and heart rate. Sibutramine gave greater occupancy of NA than serotonin reuptake sites. Coadministration of the selective 5-HT(1A

Full Text available with Trip Pro

2009 Obesity

79. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. (PubMed)

Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Low levels of bilirubin are associated with an increased risk of cardiovascular adverse events. Weight reduction is known to reduce several cardiovascular risk factors, but effects on bilirubin levels have not been reported. We studied the response of weight loss therapy with sibutramine and lifestyle change (...) on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population. Data from the first 4 weeks of the lead-in period of the Sibutramine Cardiovascular Outcome study were analyzed. A total of 10 198 patients provided body weight measurements before and after 4 weeks of sibutramine treatment (10 mg daily), of whom 1059 (10.4%) gained weight, 1467 (13.7%) lost greater than 0% to 1%, 2492 (23.2%) lost greater than 1% to 2%, 2280 (21.2%) lost greater than 2% to 3%, 1498 (13.9%) lost

2009 Metabolism: clinical and experimental Controlled trial quality: uncertain

80. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. (PubMed)

Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. Metformin is the drug of choice to treat obese type 2 diabetes patients because it reduces either insulin-resistance and body weight. We aimed to comparatively test the efficacy and tolerability of pioglitazone and sibutramine in metformin-intolerant obese type 2 diabetic patients treated with sibutramine.Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated (...) during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day). All intolerant patients to metformin received a treatment with pioglitazone (45 mg/day) and sibutramine (10 mg/day) and they were compared with fifty-three patients treated with metformin (3,000 mg/day) and sibutramine (10 mg/day) for 6 months in a single-blind controlled trial. We assessed body mass index, waist circumference, glycated hemoglobin, Fasting Plasma glucose

2009 Internal medicine (Tokyo, Japan) Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>